Portable POCT Immunofluorescence Analyzer Makes Testing Smarter, Faster and More Efficient
By LabMedica International staff writers Posted on 12 May 2023 |
With existing POCT dry fluorescence methods it can be difficult to meet the accurate and sensitive detection requirements for clinical samples. The new time-resolved fluorescence immunoassay (TRFIA) technology uses time-resolved techniques to measure fluorescence, combines long decay lifetime markers with time-resolved fluorescence, effectively eliminating non-specific fluorescence interference and greatly improving analytical sensitivity. Now, a new time-resolved immunofluorescence analyzer uses TRFIA technology to quantitatively measure the concentration of analytes in blood or other samples at the POC.
The FIA Go from Goldsite Diagnostics Inc. (Shenzhen, China) is a compact fluorescent immunoassay analyzer designed for POCT settings. The rapid, quantitative instrument is based on TRFIA technology for high precision and low interference. The high-performance portable analyzer with a wide-ranging parameter menu provides professionals with high-quality medical information and user-friendly handling.
Featuring easy operation and an Android operating system, the FIA Go analyzer supports multiple tests, including Vitamin D, Ferritin, Folic acid, hormones, thyroid panels, etc. With its one-step operation, the FIA Go analyzer provides fast and accurate results in minutes at the POC, making it suitable for delivering timely primary care at the physician's office. Other flexible application scenarios include clinical laboratories, clinical departments, emergency outpatient clinics, and ambulances.
Related Links:
Goldsite Diagnostics
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders